Fulgent Reports Fourth Quarter and Full Year 2024 Financial Results
Portfolio Pulse from
Fulgent Genetics reported its financial results for Q4 and full year 2024, with total revenue of $76.2 million and a core revenue growth of 14% year-over-year. The company reported a GAAP loss of $5.9 million, or ($0.19) per share.
February 28, 2025 | 12:15 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Fulgent Genetics reported Q4 2024 revenue of $76.2M with a 14% increase in core revenue, but faced a GAAP loss of $5.9M. This mixed result may lead to short-term volatility in the stock price.
The 14% growth in core revenue is a positive indicator of business expansion, but the GAAP loss of $5.9M could concern investors. This mixed financial performance may result in short-term stock price volatility as the market digests the results.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100